Fate Therapeutics, Inc. (FATE) Stock Forecast
FATE analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 3.82 / 5 from 11 analysts
- Price target
- $5.74 average of analyst targets
- Upside to target
- +220.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.27
- 52-week range
- $0.96 – $3.11
FATE analyst ratings
11 analystsNumber of analysts at each rating.
FATE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FATE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.28 | −$0.21 | −$0.27 | +5.6% | 8 |
| Current fiscal year (2026) | −$1.02 | −$1.11 | −$0.88 | −$1.15 | +11.5% | 8 |
| Next fiscal year (2027) | −$0.97 | −$1.30 | −$0.64 | −$1.02 | +4.9% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FATE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.2M | $0 | $2.5M | −30.9% | 12 |
| Current fiscal year (2026) | $5.6M | $3.4M | $8.4M | −15.0% | 12 |
| Next fiscal year (2027) | $4.8M | $0 | $10.0M | −15.6% | 11 |
FATE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FATE revenue: reported and forecast
FATE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.26 | −$0.26 | −$0.26 | −$0.26 | −2.7% | 4 up · 2 down |
| Current fiscal year (2026) | −$1.03 | −$1.04 | −$1.02 | −$1.02 | −$1.02 | −1.5% | 4 up · 2 down |
| Next fiscal year (2027) | −$0.99 | −$0.99 | −$0.97 | −$0.97 | −$0.97 | −2.2% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FATE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FATE beat in 10 of 12.
What analysts expect from FATE
11 analysts cover Fate Therapeutics; their consensus rating is buy (3.82 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.74, 220.9% above the latest close of $1.79. Analysts expect earnings of −$1.02 per share for 2026, +11.5% from a year earlier. For 2027 the average estimate is −$0.97 per share on revenue of $4.8 million. Fate Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: FATE income statement, FATE key metrics, FATE chart. See the FATE stock overview for the latest quote and news.
FATE forecast FAQ
What is Fate Therapeutics's price target?
The average analyst price target for Fate Therapeutics is $5.74, 220.9% above the latest close of $1.79.
Is Fate Therapeutics a buy, hold or sell?
Of 11 analysts covering Fate Therapeutics, 4 rate it a strong buy, 1 a buy, 6 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Fate Therapeutics's EPS forecast?
Analysts forecast −$1.02 per share for 2026 (range −$1.11 to −$0.88); for 2027 the estimate is −$0.97.
What is Fate Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $5.6 million, growth of −15.0%; for 2027 it is $4.8 million.
When does Fate Therapeutics report earnings?
Fate Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.27.
Does Fate Therapeutics usually beat earnings estimates?
Fate Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.